Who we are
Key topics
Publications
Factsheets
Infographics
Reports
Policy
Videos
Podcast – Conversations on EU Pharma
Newsroom
Press releases
In the news
Press kit
JOB OPPORTUNITIES
Contact us
Login
Generic medicines
Home
Medicines for Europe
Generic medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Biosimilar medicines
Home
Medicines for Europe
Biosimilar medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
DEFINITION
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
External resources
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Value added medicines
Home
Who we are
Value added medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Environment of value added medicines in Europe
Definition
THERAPEUTIC AREAS
Q&A
What’s new
Environment of value added medicines in Europe
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Value Added Medicines award 2019
QUOTES
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Contact us
Events
Newsroom
News about
By type
In the news
Press releases
Twitter
Tweets
Videos
Photos
Adjust prices to save drugs, generics industry tells EU
6 February 2023
Open
Read more
OPEN LETTER Time for a new medicine security contract for Europe
1 February 2023
Open
Everything you wanted to know about the EU’s pharma reform (but were too afraid to ask)
17 January 2023
Can the European Union bring eye-wateringly expensive medicines to the […]
Read more
EU can do more for equitable access to medicines
12 January 2023
Open
IGBA taking action to tackle shortages of antibiotic medicines
22 December 2022
Open
Commission study highlights need for procurement reform to ensure patient access to medicines
21 December 2022
Open
Billions more euros to re-invest in better healthcare thanks to biosimilar medicines
13 December 2022
Open
Ready in a crisis: Medicines for Europe commits at one year anniversary of HERA
8 December 2022
Open
2022 Health at a Glance Report highlights the need to rethink investments in health after the COVID-19 pandemic
5 December 2022
Open
Giving medicines a new life: EU should foster patients’ access to Value Added Medicines
30 November 2022
Open
Posts navigation
1
2
3
…
32
Subscribe to our newsletter
Medicines For Europe
Who we are
WHO WE ARE – ABOUT MEDICINES FOR EUROPE
Purpose and Objectives
OUR VALUES
STRUCTURE
OUR MEMBERS
BECOME A MEMBER
CODE OF CONDUCT
DISCLOSURE
JOB OPPORTUNITIES
Key topics
COVID-19
Access
INDUSTRIAL POLICY
REGULATORY AND LEGAL FRAMEWORK
FALSIFIED MEDICINES
ENVIRONMENT
ANTIMICROBIAL RESISTANCE
MEDICINE SHORTAGES
Publications
Factsheets
Infographics
Reports
Policy
Videos
Podcast – Conversations on EU Pharma
Newsroom
Press releases
In the news
Press kit
Contact us
SECTOR GROUPS
Generic medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Biosimilar medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Value added medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
Events
Tweet
Tweet
Tweet
LinkedIn